4.4 Article

Encapsulation of morin in lipid core/PLGA shell nanoparticles significantly enhances its anti-inflammatory activity and oral bioavailability

Journal

SAUDI PHARMACEUTICAL JOURNAL
Volume 31, Issue 6, Pages 845-853

Publisher

ELSEVIER
DOI: 10.1016/j.jsps.2023.04.010

Keywords

Anti-inflammatory; Bioavailability; Morin; Nanoencapsulation; PLGA

Ask authors/readers for more resources

This study developed a nanoparticle formulation to improve the bioactivity and oral bioavailability of MR, a bioactive plant polyphenol. The optimal nanoparticles were about 200nm in size with an almost neutral surface charge and a loading efficiency of 82%. The nanoparticles exhibited sustained release of MR, showed enhanced anti-inflammatory activity, and achieved a 5.6-fold increase in bioavailability and prolonged plasma half-life when orally administered to mice.
Morin (3,5,7,20,40-pentahydroxyflavone; MR) is a bioactive plant polyphenol whose therapeutic efficacy is hindered by its poor biopharmaceutical properties. The purpose of this study was to develop a nanopar-ticle (NP) formulation to enhance the bioactivity and oral bioavailability of MR. The nanoprecipitation technique was employed to encapsulate MR in lipid-cored poly(lactide-co-glycolide) (PLGA) NPs. The optimal NPs were about 200 nm in size with an almost neutral surface charge and a loading efficiency of 82%. The NPs exhibited sustained release of MR within 24 h. In vitro antioxidant assays showed that MR encapsulation did not affect its antioxidant activity. On the other hand, anti-inflammatory assays in lipopolysaccharide-stimulated macrophages revealed a superior anti-inflammatory activity of MR NPs compared to free MR. Furthermore, oral administration of MR NPs to mice at a single dose of 20 mg/kg MR achieved a 5.6-fold enhancement in bioavailability and a prolongation of plasma half-life from 0.13 to 0.98 h. The results of this study present a promising NP formulation for MR which can enhance its oral bioavailability and bioactivity for the treatment of different diseases such as inflammation.(c) 2023 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available